title: Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
authors.affiliation: a Division of Hematologic Malignancies , Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
authors.affiliation: a Division of Hematologic Malignancies , Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
authors.affiliation: a Division of Hematologic Malignancies , Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D019943:Amino Acid Substitution; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007930:Leucine / Q000235:genetics; D020125:Mutation, Missense; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics*; D010880:Piperidines; D011392:Proline / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology
chemical_list: D007074:Immunoglobulin G; C507779:MYD88 protein, human; D053594:Myeloid Differentiation Factor 88; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011392:Proline; D007930:Leucine; D000225:Adenine